Back to News
Market Impact: 0.25
Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue Estimates
Source: zacks.com
Corporate EarningsAnalyst EstimatesCompany Fundamentals
Castle Biosciences reported a quarterly loss of $0.13 per share, narrower than the Zacks Consensus Estimate of a $0.38 loss. The loss widened from $0.02 per share in the year-ago period.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.10
Ticker Sentiment
CSTL0.45
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook